Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > AstraZeneca's ADC disappoints - on severe adverse events

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jul 01, 2024 10:32am

77 Views

Post# 36113244

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse events

July 01, 2024 - Daiichi Sankyo wins patent dispute with Pfizer/Seagen over technologies used in the Japanese pharma's AstraZeneca-partnered antibody-drug conjugate Enhertu (fam-trastuzumab deruxtecan).

https://www.biospace.com/article/daiichi-sankyo-wins-47m-in-adc-patent-arbitration-with-seagen-pfizer-dispute-looms/

<< Previous

Bullboard Posts

Next >>

A PGM mining stock with value written all over it